TIM4 expression by dendritic cells mediates uptake of tumor-associated antigens and anti-tumor responses by Caronni, Nicoletta et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2021 
TIM4 expression by dendritic cells mediates uptake of tumor-




Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
ARTICLE
TIM4 expression by dendritic cells mediates uptake
of tumor-associated antigens and anti-tumor
responses
Nicoletta Caronni1,2,18✉, Giulia Maria Piperno1,18, Francesca Simoncello1, Oriana Romano 3, Simone Vodret4,
Yuichi Yanagihashi5, Regine Dress 6, Charles-Antoine Dutertre6, Mattia Bugatti7, Pierre Bourdeley8,
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Serena Zacchigna 4,13, Renato Ostuni 2,14, Pierre Guermonprez 8, William Vermi 7,15,
Florent Ginhoux 6,16,17, Silvio Bicciato 3, Shigekatzu Nagata 5 & Federica Benvenuti1✉
Acquisition of cell-associated tumor antigens by type 1 dendritic cells (cDC1) is essential to
induce and sustain tumor specific CD8+ T cells via cross-presentation. Here we show that
capture and engulfment of cell associated antigens by tissue resident lung cDC1 is inhibited
during progression of mouse lung tumors. Mechanistically, loss of phagocytosis is linked to
tumor-mediated downregulation of the phosphatidylserine receptor TIM4, that is highly
expressed in normal lung resident cDC1. TIM4 receptor blockade and conditional cDC1
deletion impair activation of tumor specific CD8+ T cells and promote tumor progression. In
human lung adenocarcinomas, TIM4 transcripts increase the prognostic value of a
cDC1 signature and predict responses to PD-1 treatment. Thus, TIM4 on lung resident cDC1
contributes to immune surveillance and its expression is suppressed in advanced tumors.
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T issue resident Batf3-dependent type 1 dendritic cells (DCs),named cDC1, excel in activation of CD8+ T cells to exo-genously acquired antigens, and are essential to detect
tumors and to mediate rejection of nascent lesions1–4. Moreover,
intratumoral cDC1 support the function of T cells during T-cell
mediated immune clearance5,6, and their abundance in several
human cancers correlates with better prognosis5,7,8. cDC1 accu-
mulation in tumors depends on NK cells and CCL58,9 and cause, in
turn, recruitment and expansion of tumor specific T cells in situ7,10.
These positive correlations likely reflect residual cDC1 activity, as
many reports suggest that DCs are negatively affected by signals
present in the tumor immune microenvironment (TME)10–18.
Previous work established that cDC1-mediated anti-tumor
immunity primarily relies on engulfment of dying tumor cells to
acquire cell-associated antigens5,6,16. Still, the receptors that control
acquisition of tumor cell-associated antigens by cDC1 in tumor
tissues, and whether this process is targeted by the suppressive TME
has not been investigated. Putative receptors such as CD36, DEC-
205, DNGR1/Clec9A, SCARF1 and AXL control recognition/
binding of dying cells and cross-presentation of cell associated
antigens by cDC119–24, in various contexts. TIM4 (T-cell immu-
noglobulin mucin-4), that recognizes phosphatidylserine (PtdSer)
on apoptotic cells (AC), is predominantly expressed on resident
peritoneal macrophages25–27 and some subsets of DCs28–32. The
expression of these phagocytic receptors on tissue resident cDC1,
their contribution to tumor antigen uptake and modulation during
tumor growth remains however poorly explored.
In this study, we use a transplantable orthotopic KP model of
adenocarcinoma of the lung (derived from Kras/p53 KP
mice16,33,34) to study the ability of lung resident cDC1 to engulf
cell-associated antigens during tumor development. cDC1 actively
engulf and present cell-associated antigens to CD8+ T cells at
early stages of tumor development, yet antigen uptake, presenta-
tion and T cell activation is inhibited in advanced tumors. Gene
expression profiling show high expression of TIM4 in normal
lungs cDC1 and its downregulation in cells associated with late
tumors. In addition, profiling across lung phagocytes indicates
that, unlike what has been described in other tissues, TIM4 is not
expressed on lung resident macrophages or macrophages asso-
ciated to lung tumors. Receptor blockade and cDC1 genetic
deletion of TIM4 regulates the capacity of cDC1 to engulf dying
cells and tumor cells in the lung, and to induce cancer specific
CD8 responses that control tumor growth. In human lung ade-
nocarcinomas a combined cDC1/Timd4 gene signature predicts
survival in early stages patients, and responses to PD-1 treatment
in a cohort of lung adenocarcinoma patients.
Results
cDC1 fail to uptake cell associated antigens in late lung tumors
tissue. To explore uptake of cell associated antigens by lung resident
cDC1 during tumor development, we established orthotopic tumors
by intravenous inoculation (i.v.) of KrasG12D/+;p53−/− primary
tumor cells (KP)33,34. We defined two time points for analysis, early
tumors (KP(e), days 10–14) when the tumor area occupies between
5–10% of the lung parenchyma and a late time point, when nodules
occupy more than 30% of the total lung area (KP (l), days 28–35)
(Supplementary Fig. 1a). Mice injected with PBS were used as control
(normal lungs, nLung). Established tumors showed an increased
frequency of neutrophils, unchanged frequencies of SiglecF+ CD11c+
alveolar macrophages (AM) and Ly6C monocytes and decreased
frequencies of T cells (Supplementary Fig. 1b). The DCs compart-
ment (Supplementary Fig. S1c–e) in late tumors was characterized by
an increment of mo-DCs and cDC2 over cDC1, in line with previous
data16,18. Expression of cDC1 lineage specific and maturation mar-
kers was not affected in tumor-associated cDC1 (Supplementary
Fig. 1f). To examine the ability of cDC1 to engulf dying cells, we first
administered labeled apoptotic thymocytes intratracheally (i.t.) to
control or tumor bearing animals. Quantification of fluorescence
associated with phagocytes 2 h after inoculation showed a high
uptake by AM and a lower uptake by cDC1 and cDC2 (Figs. 1a and
S2a). Uptake by cDC2 and AM remained unchanged in early and late
tumors as compared to controls, whereas uptake by cDC1 was sig-
nificantly inhibited in late tumors (Fig. 1a). To directly examine the
uptake of cellular tumor fragments in tissues, we generated a KP-BFP
reporter line. At early time points after tumor inoculation we
observed a higher BFP fluorescence in lung cDC1 than in cDC2 and
AM, likely due to faster degradation of endocytic cargo in the latter
subsets (Supplementary Fig. 2b)5,35. In more advanced tumors, BFP
associated with cDC1 was significantly decreased whereas it remained
unchanged in cDC2 and AM, suggesting a selective reduction in the
capacity to engulf tumor cells by cDC1 (Fig. 1b and Supplementary
Fig. 2b). To visualize the uptake at the singe cell level we next isolated
cDC1 from control, early, and late KP tumor-bearing mice and
incubated them ex-vivo with labeled apoptotic thymocytes. cDC1
from normal lung and early tumors captured and engulfed dying
cells efficiently. In contrast, cDC1 isolated from late tumors were
impaired in binding to and phagocytosis of dying cells (Fig. 1c, d and
Supplementary Fig. 2c, d). We concluded that the TME of KP tumors
inhibits the intrinsic capacity of cDC1 to engulf dying cells. cDC1
preferentially cross-present tumor associated antigens acquired via
phagocytosis to activate tumor specific CD8+ T cells5,6,24. To
understand the impact of defective uptake on the capacity to cross-
present antigens, we generated a KP-OVA line expressing low levels
of the model antigen OVA (OVA, clone G11, Supplementary
Fig. 3A). KP-OVA tumors grew less than the parental KP tumors
and showed smaller nodules at late time points (Supplementary
Fig. 3b). Depletion of CD8+ T cells during the first 2 weeks upon
tumor challenge led to a dramatic increase in tumor burden indi-
cating that tumor containment was mediated by CD8+ T cells
(Supplementary Fig. 3c). Staining with the 25D-1.16 antibody to
detect cross-presented peptide:MHC OVA on tissue cDC1 showed
high antigen density in early KP-OVA tumor bearing lungs and low
signal in late tumor bearing lungs (Fig. 1e and Supplementary
Fig. 3d). To further probe changes in the capacity to cross-present
tumor associated antigens we isolated cDC1, cDC2, and AM from
mice bearing early or late KP-OVA tumors. In early tumors, cDC1
were the only subset capable of inducing efficient activation of OVA
specific CD8, in line with previous reports (Fig. 1f and Supplemen-
tary Fig. 3e)3,5,6,36. This property was significantly inhibited in cDC1
from late tumors indicating that cross-presentation of antigens
picked-up in tumor tissue is lost in advanced tumors (Fig. 1f). To
confirm suppression of cross-presentation of cell-associated antigens,
we delivered OVA-loaded apoptotic thymocytes in the lung.
CD8 T cells proliferated in control and early tumor bearing animals
but not in in late tumor bearing animals (Fig. 1g). Spontaneous IL-12
production in vivo was slightly decreased yet cells responded effi-
ciently to ex-vivo restimulation suggesting that cytokine signals by
DC1 are not deeply compromised (Supplementary Fig. 3f, g). In
addition, peptide pulsed cDC1 induced robust activation of OVA
specific CD8+ T cells, indicating normal interaction with T cells and
no impairment in co-stimulatory signals (Supplementary Fig. 3i).
Cross-presentation of soluble protein antigens delivered ex-vivo was
diminished in late tumor cDC1, in line with previous reports13
(Supplementary Fig. 3j). Thus, by dissecting individual steps of DC1
activity, we evidenced a primary defect in antigen capture by tumor
tissues resident cDC1.
Lung cDC1 fail to activate CD8+ tumor responses in late
tumors. To examine whether reduced antigen presentation by
cDC1 along with tumor progression correlates to impairment of
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CD8+ T cell responses in vivo, we tracked endogenous CD8+ T
cell over time in the blood of animals challenged with KP-OVA.
Circulating IFN-γ+ CD8+ T cells were observed by day 14 after
challenge, peaked at day 21 and declined to almost baseline by
day 28 (Fig. 2a, b). The same trend was observed in lung tissue
CD8+ T cells when comparing early and late time points (Fig. 2c).
Immunohistochemistry showed high density of CD8+ T cells in
early nodules as opposed to few CD8+ T cells confined at the
tumor border in late tumors (Fig. 2d). Because loss of T cell
responses may have resulted from selection of OVA negative
tumor cells in late tumors33, we verified OVA expression by flow
cytometry and immunohistochemistry. The percentage of OVA
expressing CD45− cells was similar in early and late tumors
(Supplementary Fig. 4a). The intensity of OVA staining was
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similar in small nodules in early tumors and large nodules in late
tumors (Supplementary Fig. 4b), indicating that the antigen is still
expressed in advanced lesions. To distinguish cell intrinsic
exhaustion of CD8+ T cells from defective antigen presentation,
we analyzed proliferation of naïve CFSE labeled CD8+ OVA
specific T cells transferred into early and late tumor bearing-
lungs. Proliferation was induced efficiently in early tumors but
not in late tumors, suggesting lack of priming by APC in situ
(Fig. 2e, f). In addition, proliferation was reduced in Batf3−/−
mice3, indicating that cDC1 are required for full T cell activation
in this model (Fig. 2g, h). Together these data indicate that
inefficient priming of tumor specific CD8+ T cells in established
tumors coincides with loss of antigen presentation by tissue
resident cDC1.
Gene expression profiling shows loss of TIM4 in lung tumor
associated cDC1. To explore the molecular basis of loss of antigen
acquisition in late tumor, we compared the transcriptional profile
of cDC1 isolated from control lung (nLung) or late KP tumor-
bearing lungs. Factors defining the cDC1 lineage were similarly
expressed in control and tumor associated KP cDC1, indicating
that cDC1 maintained their identity (Fig. 3a). Gene expression
analysis returned more than 40 differentially expressed transcripts
(false discovery rate ≤5% and absolute fold change ≥2; Supple-
mentary Fig. 5a and Supplementary Table 1). Transcripts enriched
in tumor-associated cDC1 belonged preferentially to the interferon
alpha pathway, intracellular trafficking and antigen processing
(Supplementary Fig. 5b–d). We focused on phagocytic receptors to
find a mechanism for loss of antigen uptake. As shown in Fig. 3b, c;
Timd4, encoding for the PtdSer receptor TIM425, was highly
expressed in nLung cDC1 and strongly downregulated in late
tumors. Other receptors implicated in binding and engulfment of
apoptotic cells (Clec9a, Cd36, Axl, Lrp11, Ly75, Stab1, MerTK,
Marco,Tyro3, Scarf1) showed no significant modulation, with the
exception of Cd300lf, a second receptor for PtdSer known to inhibit
efferocytosis in DCs37, and Cd209a (DC-SIGN), which was slightly
down-modulated. Since selective high expression of TIM4 by lung
cDC1 had never been reported we validated our data by analysis of
publicly available datasets. Tabula Muris single cells dataset from
normal lung tissues (Nature. https://doi.org/10.1038/s41586-018-
0590-4) confirmed co-expression of Timd4 with markers of cDC1
in a cluster of myeloid cells (Fig. 3d). Importantly, analysis of a
recently generated scRNA dataset from control and KP tumor
murine lungs16 confirmed selective expression of TIM4 in the
cDC1 subset and a significant decrease in tumors condition
(Fig. 3e). Flow cytometry confirmed high expression of TIM4
protein in lung cDC1 and lack of expression in the other lung
phagocytic subsets (Supplementary Fig. 6a, b). Further profiling
across multiple mouse tissues38 showed the expected high
expression in tissue resident macrophages, in a consistent fraction
of Langerhans cells in the skin and in a fraction of dermal cDC132.
Slight TIM4 expression was present on liver cDC1, on a small
fraction of migratory cDC1/cDC2 in mediastinal LNs and in
splenic and bone marrow cDC1/cDC2, confirming the highest
expression on lung cDC1 in naive mice (Supplementary Fig. 6c, d).
To verify the kinetic of TIM4 downregulation in tumors we
analyzed early stages that correspond to functional cDC1. We
observed a slight, not significant, trend of reduction (Fig. 3f),
providing a causal link between receptor levels and engulfment
capacity (Fig. 1a, b). Interestingly, orthotopic KP injection in one
lobe was sufficient to induce a slight reduction in the contra-lateral
lobe (Supplementary Fig. 7a). Expression was not detected in any
of the other lung phagocytes in late tumors, including TAMs, nor
in the stroma or tumor cells (CD45 negative fraction) (Fig. 3g), in
contrast to previous data in breast tumors and melanoma29,31. A
slight reduction in TIM4 was observed also in early autochthonous
KP tumors (Supplementary Fig. 7b), and in cDC1 associated to
Lewis lung carcinoma tumors (Supplementary Fig. 7c).
TIM4 on lung cDC1 control uptake of cell-associated antigens.
TIM4 plays a non-redundant role for tethering and engulfment of
apoptotic cells in peritoneal macrophages27,39. Whether TIM4
may function as a receptor for dead-cell uptake in the DCs
compartment or in cDC1, is poorly documented28. To analyze the
role of TIM4 during engulfment of BFP-KP cells, we first verified
exposure of phosphatidylserine by tumor cells growing in lung
tissues (Supplementary Fig. 7d). We next administered TIM4
blocking antibodies or isotype controls during the initial phases of
tumor engraftment. Receptor blockade was effective and did not
alter maturation or absolute numbers of phagocytes excluding
bystander effects (Supplementary Fig. 7e). TIM4 blockade caused
a significant reduction in the fraction of cDC1 engulfing BFP
tumor cells, without affecting the uptake by the other subsets
(Fig. 4a and Supplementary Fig. 7f). We further tested the impact
Fig. 1 Uptake of cell associated tumor antigens by cDC1 is inhibited in advanced lung tumors. a Control mice (nLung), or mice carrying early (e) or late
(l) KP tumors were challenged i.t. with CTV labeled apoptotic thymocytes. Two hours later total lung cell suspensions were analyzed by flow-cytometry to
assess the fraction of phagocytes associated to fluorescence. Representative flow cytometry plots of cDC1 (gated on CD45+/Cd11c+/SiglechF−/MHC-
IIhigh/CD11b−) and quantification of uptake, expressed as percentage of CTV+ cDC1. Data were examined over two independent experiments: nLung n= 8,
KP(e) n= 5, KP(l) n= 5, one-way ANOVA followed by Tukey’s post-test. b Mice were challenged with KP-BFP cells. Lungs were harvested at early or late
time points after challenge to prepare total lung cell suspensions. Representative flow cytometry plots displaying the percentage of BFP+ cDC1 and the
corresponding quantification. Data are pooled from two experiments with n= 8 mice per group, two-tailed unpaired t-test. c, d Sorted-cDC1 cells from
nLung, early or late whole tumor tissues were incubated for 30’ (binding, c) or 2 h (uptake, d) with CFSE labeled apoptotic thymocytes. c Representative
micrographs showing cDC1 binding to thymocytes. The percentage of cDC1 in contact with at least one thymocyte was quantified on 30 individual
cells acquired on separated fields in two independent experiments. d Representative micrographs showing thymocytes uptake. The percentage of
cDC1 that has engulfed at least one cellular fragment is plotted as uptake. Data are representative of 30 cells/condition in two independent experiments. In
c and d one-way ANOVA followed by Tukey’s post-test. e Tumors were induced by i.v. injection of KP-OVA expressing cells. Cross-presentation by lung
cDC1 was detected by flow cytometry on whole lung tissues by labeling with peptide:MHC OVA specific antibody (25D1.16) (gated on CD45+/Cd11c+/
Siglech-F−/MHC-IIhigh/CD11b−). Representative histograms and quantification of the percentage of positive cells based on the gate depicted on
histograms. Data are from two independent experiments: KP(e) n= 4, KP(l) n= 3 (cDC1 were pooled from two mice for analysis), two-tailed unpaired
t-test. f cDC1 were sorted from whole lung cell suspension of early and late KP-OVA bearing tumors and mixed with CFSE-labeled OVA specific T cells
(OT-I). Representative CFSE peaks and quantification of proliferation (cells undergoing at least two cycles of proliferation over total T cells). Each point
corresponds to cDC1 isolated from KP(e) n= 3 or KP(l) n= 4 mice in three independent experiments, two-tailed unpaired t-test. g CSFE labeled OT-I were
transferred into nLung, early, and late tumor bearing animals. OVA-loaded apoptotic thymocytes were administered i.t. and T cell proliferation in the
mediastinal lymph node (MLN) was evaluated 2 days later. Data are from two independent experiments, nLung n= 9/7, KP(e) n= 4 or KP(l) n= 7,
one-way ANOVA followed by Tukey’s post-test. All data are expressed as mean ± SEM. Source data are provided as a Source Data file.
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Fig. 2 CD8+ T cell responses and cross-presentation of tumor antigens by cDC1 are inhibited in late tumors. a, b Representative plots and quantification
of the kinetic of IFN-γ production by endogenous blood CD8+ T cells in KP-OVA challenged mice. Data are from two independent experiments at day 7–28
or 3 independent experiments at day 14–21. In b Kruskal–Wallis followed by Dunn’s post-test day 7 n= 6, day 14 n= 15, day 21 n= 6, day 28 n= 4 mice.
c Percentage of IFN-γ producing endogenous CD8+ T cells in lungs bearing early or late KP-OVA tumors. KP(e) n= 7, KP(l) n= 8 mice in two independent
experiments, two-tailed unpaired t-test. d CD8+ T cells localization in early and late KP-OVA tumors. Scale bar 200 µm. Quantification of the density of
CD8+ T cells as a function of the nodule area was calculated automatically on three consecutive sections/sample. Data are from KP(e) n= 11, KP(l) n= 7,
two-tailed unpaired t-test. e, f Proliferation profile of OT-I in the MLN (e) or lung (f) of mice bearing early or late KP-OVA tumors was measured 2 days
after transfer. Proliferation index (cells that underwent at least two cycles of proliferation) and absolute numbers of proliferated cells are depicted. In e %
of proliferation KP(e) n= 12, KP(l) n= 7; absolute numbers KP(e) n= 6, KP(l) n= 4. In f %proliferation KP(e) n= 12, KP(l) n= 7; absolute numbers KP(e)
n= 7, KP(l) n= 5. Data are from three independent experiments, two-tailed unpaired t-test. g, h KP-OVA tumors were induced in WT and Batf3−/− mice.
g Proliferation and IFN-γ production of adoptively transferred OVA specific CD8 T cells and IFN-γ production by endogenous CD8+ T cells in the lung. %
proliferation WT n= 3, Batf3−/− n= 3; IFNγ+OTI (%) and IFNγ+CD45.2+CD8(%) WT n= 4, Batf3−/− n= 4; two-tailed unpaired t-test. h IFN-γ
production by OT-I in MLNs. Data represent one of two independent experiments (n= 4 mice/group), two-tailed unpaired t-test. All data are expressed as
mean ± SEM. Source data are provided as a Source Data file.
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of TIM4 blockade on phagocytosis of dying thymocytes. TIM4
blocking antibodies in nLung selectively reduced the uptake by
cDC1 almost to the level found in KP tumors, and had no
additive effect when administered to tumor lungs (Fig. 4b)
(Supplementary Fig. 7g). Uptake was reduced as well in cDC1
isolated from wt or Timd4−/− mice and incubated with apoptotic
thymocytes labeled with pH Rodo, a probe that becomes
fluorescent only under acidic conditions39,40 (Fig. 4c). Blockade
or genetic deletion of TIM4 impacted similarly on the subsequent
step of antigen presentation. Blocking antibodies decreased
antigen presentation of KP-OVA antigens (peptide:MHC OVA
complexes labeling) by tissue cDC1 (Fig. 4d), and proliferation of
adoptively transferred CD8 T cells into mice receiving OVA
loaded apoptotic thymocytes (Fig. 4e). Finally, cDC1 isolated
Fig. 3 Selective cDC1 expression of the PtdSer receptor TIM4 in lung phagocytes and downregulation in tumors. a cDC1 were isolated from nLung or
late KP tumors to analyze transcriptional profiles. The graph shows expression of cDC1 and cDC2 lineage specific genes in nLung-sorted and tumor-sorted
cDC1. Data are expressed as mean ± SD with nLung n= 4, KP(l) n= 3. b Volcano plot showing the fold change of genes encoding scavenger receptors
(significantly modulated genes are depicted in red and blue, using a q-value < 5%, a false discovery rate (FDR)≤ 5% and a fold change ≥2 or ≤2), using the
Significance Analysis of Microarray (SAM) algorithm. c The dot-plot shows the relative abundance of genes in b using a color and size scale of linear
expression values. d T-distributed stochastic neighbor embedding (tSNE) plots of single cells expression profiles in mouse lungs (Tabula Muris). Colors
represent clusters of different subsets based on global similarity of gene expression. The cluster corresponding to DC-macrophages was further analyzed
to assess co-expression of cDC1 markers and Timd4 transcripts, as depicted in the boxes. e scRNA seq of naive and KP lung tumors from16 were analyzed
to visualize Timd4-expressing cells in three subpopulation of lung DCs. Violin plots show expression of Timd4 in cDC1, cDC2, and mregDCs. Statistical
analysis was performed using Seurat R package, taking in consideration both number of expressing cells and levels of expression. f Representative
histograms and quantification of the percentage of cells expressing TIM4 in nLung, early and late lung tumors (the gate for identification of positive and
negative cells is depicted in the histogram). Data are from nLung n= 3, KP(e) n= 6, KP(l) n= 9 mice. Significance was determined by one-way ANOVA
followed by Tukey’s post-test; data are expressed as mean ± SEM. g Representative histograms of TIM4 expression on total CD45− and CD45+ cells and
all lung phagocytic subsets in nLung and late KP lungs. Alveolar macrophages (AM), interstitial macrophages (IM), tumor associated macrophages (TAM),
monocytes (Mono). Each peak is overlaid on the corresponding FMO controls (black line). Source data are provided as a Source Data file.
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from early KP-OVA lungs of animals treated with TIM4 blocking
Abs failed to induce proliferation of OVA specific T cells ex-vivo
(Fig. 4f). The same reduction was observed when using Tim4−/−
animals as recipient (Fig. 4g). We concluded that TIM4 expres-
sion in lung cDC1 is required to capture and present cell-
associated antigens in normal lungs and early tumor tissues.
TIM4 controls initiation of anti-tumor CD8 immunity.
To directly assess the impact of TIM4-mediated engulfment on
anti-tumor CD8 responses we administered TIM4 blocking anti-
bodies during tumor challenge. TIM4 blockade prevented induction
of OVA specific endogenous effector CD8+ T cells in the peripheral
blood of KP challenged mice (Fig. 5a), and reduced the activation of
adoptively transferred OVA specific T cells (Supplementary Fig. 7h).
To further investigate the impact of TIM4 during T cell priming we
inoculated KP-OVA tumors into wild-type or Timd4−/− animals.
Numbers of IFN-γ+ CD8+ T cells at day 7 after challenge were
significantly decreased in Timd4−/− mice as compared to WT
controls (Fig. 5b). Moreover, absolute numbers of total CD8+ T cells
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and OVA pentamer CD8+ were diminished in the lung of Timd4−/−
mice (Fig. 5c, d). To overcome potential bystander effects of systemic
TIM4 blockade and pinpoint precisely on cDC1, we generated mixed
bone marrow chimeras using mixtures of wild-type:Batf3−/− or
Timd4−/−Batf3−/− bone marrow (Supplementary Fig. 8a–c). IFN-γ
production and accumulation of CD8+ T cells was decreased in
animals carrying a specific deletion of TIM4 in the cDC1 compart-
ment (Fig. 5e, f). Most importantly, containment of tumor growth
was reduced in Timd4−/−:Batf3−/− chimeras as shown by more
abundant lesions and larger nodules than in animals reconstituted
with wild-type:Batf3−/− bone marrows (Fig. 5g). Thus, selective
ablation of TIM4 in cDC1 reduces protective anti-tumor responses.
We finally tested whether TIM4 contributes to rejection induced by
immunogenic chemotherapy, which favor APC activation41,42. We
used a combination of oxaliplatin and cyclophosphamide (oxa/cycl),
previously shown to induce CD8+ T cell responses and rejection in
this same KP model34. Animals were challenged with KP tumors and
treated with oxa/cycl at day 7 and 14 after challenge (Fig. 6a). The
drug increased CD8/CD4 ratio both in LNs and lung tissues and
significantly reduced tumor burden with respect to untreated animals
(Fig. 6b–d). The efficacy of oxa/cycl treatment was abrogated in
Batf3−/− mice (Fig. 6e), indicating that responses induced by
immunogenic therapy require cDC1 in this model. Of note, addition
of TIM4 blocking antibodies one day before oxa/cycl administration
resulted in reduced efficacy of immunogenic therapy (Fig. 6b–d),
denoting that TIM4 plays a role during capture of drug-induced
apoptotic cells to induce anti-tumor responses.
TIM4 expression in lung adenocarcinomas correlates with
signatures of protective immune cells and predicts responses to
PD-1 checkpoint blockade. To investigate the relevance of our
observations in human cancers, we explored TIM4 expression in
the Cancer Genoma Atlas (TCGA) dataset. We found a correla-
tion between Timd4 transcripts and a gene signature specific for
human cDC1 and CD8 effector T cells in early stage patients
(Fig. 7a) (Supplementary Table 2 and refs. 7,8). To further explore
the potential prognostic impact of TIM4, we analyzed
Kaplan–Meier survival curves in the TCGA dataset of lung ade-
nocarcinoma. Interestingly, early-stage patients expressing a high
cDC1 signature complemented by Timd4 showed a small yet
significant advantage in survival (Fig. 7b). Based on these obser-
vations, we reasoned that TIM4 may be important to determine
responsiveness to therapies that promote CD8 responses. To this
goal, we analyzed a recent dataset comparing the transcriptional
profiles before treatment of responders and non-responders to
anti PD-1 immunotherapy (GSE126044). Remarkably, Timd4
expression was significantly higher in patients who responded to
therapy than in non-responders (Fig. 7c), suggesting that TIM4
confers an advantage under the selective pressure of immu-
notherapy. A cDC1 signature and a CD8 effector signature had a
similar predictive power of positive responses to therapy (Fig. 7d),
indicating that Timd4 could be an additional biomarker to identify
tumors with intact antigen presentation.
Discussion
Cells of the myeloid lineage have been delineated with increasing
precisions in the TME revealing their complexity, plasticity, and
key roles in promoting or restricting tumor growth. Among these,
cDC1 have emerged as invariably linked to positive outcomes
across multiple preclinical models and human tumors5–8,16. A
key function enabling cDC1 anti tumoral properties is the effi-
cient capture and internalization of tumor cell fragments for
cross-presentation to CD8+ T cells5,6,19–21,36,43,44. Here, we show
that this exquisite cDC1 property is targeted by the micro-
environment of lung adenocarcinoma. Past investigations to
explain suppression of DCs activity in the TME have mostly
focused on post internalization events like processing of soluble
antigen, cellular metabolism, reduced maturation10–12,14,45. In
contrast, the mechanism underlying acquisition of tumor anti-
gens in tissues, and its modulation during tumor progression
have been poorly explored. By comparing cDC1 resident in
healthy lung tissues to those exposed to early or late lung tumors,
we have been able to trace the evolution of antigen capture as a
function of tumor progression. We uncover that cDC1 are key to
sample tumor antigens and initiate tumor specific CD8 responses
in early lesions. Instead, at later tumor stages, antigen acquisition
become inefficient, coinciding with loss of antigen presentation
and fading of T cell responses. Thus, a major hurdle to sustain
tumor specific CD8 responses is suppression of antigen acquisi-
tion by the most efficient cross-presenting subset in tissues.
By analyzing expression of scavenger receptors, we identified
the loss of the PtdSer receptor TIM4 as one major mechanism
underlying cDC1 deactivation in lung murine tumors. Additional
cell intrinsic changes, such as defective cross-presentation and
impaired cytokine production, likely contribute to overall
cDC1 suppression. However, by impinging on the initial step of
antigen acquisition, we propose that loss of TIM4 may dominate
over downstream events. The uptake of dead cells has been
attributed to selective expression of receptors, that are capable to
bind to and promote engulfment of dying cells in cDC119–24.
These studies were mostly performed using lymphoid resident
cDC1 and model antigens, whereas the receptors involved in
Fig. 4 TIM4 controls capture and cross-presentation of cell-associated antigens in lung resident cDC1. aMice were challenged with KP-BFP and treated
with blocking antibodies to TIM4 or isotype control as depicted. The uptake by lung cDC1 was quantified 5 days after tumor challenge. Dot plot and
quantification of one representative of two experiment with n= 3 mice/group are shown. b Control mice or late KP tumor bearing mice were pre-treated
with isotype control or αTIM4 antibodies and challenged with CTV-labeled apoptotic thymocytes. The percentage of lung phagocytes associated to
fluorescence was evaluated by flow-cytometry 2 h after challenge. Representative plots and quantification of two independent experiments are shown,
Isotype n= 7, Isotype KP(l) = 9, αTIM4 n= 8, αTIM4-KP(l) n= 3. c Uptake of pH rodo loaded thymocytes by lung cDC1 in WT and Timd4−/− mice.
Representative histograms and quantifications (percentage and MFI of pH rodo+ cDC1) for one of three independent experiments with n= 3 mice/group
are shown. d Cross-presentation by lung cDC1 (labeling with 25D1.16 antibody specific for MHC class-I:OVA peptide complex) in day 7 KP-OVA bearing
animals treated with TIM4 blockade. Representative histograms showing MFI values and quantification of five animals/group in two independent
experiments. e In vivo proliferation of adoptively transferred OT-I induced by i.t. injection of OVA-loaded apoptotic thymocytes, in the presence of TIM4
blocking antibodies or isotype control as depicted in the scheme. Graphs show frequencies and absolute numbers of proliferated CD8+ T cells in the MLN
(at least one cycle of proliferation). Data are representative of two independent experiments. % proliferation Isotype n= 8, αTIM4 n= 7; Absolute
numbers five mice/group. f Ex-vivo OT-I proliferation induced by cell-sorted cDC1 from day 7 KP-OVA lung tumors under TIM4 blockade or isotype
treatment. Representative dilution profile and quantification from three independent experiments (each point corresponds to the pool cDC1 from three
mice), Isotype n= 9, αTIM4 n= 7. g As in f, cDC1 were isolated from day 7 KP-OVA lung tumors induced in WT or Tim4d−/− animals (n= 5 mice in two
independent experiments). All data are depicted as mean ± SEM. Significance was determined by one-way ANOVA followed by Tukey’s post-test for b, or
two-tailed unpaired t-test. Source data are provided as a Source Data file.
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Fig. 5 TIM4 promotes anti-tumor CD8+ T cell responses and tumor control. a Effect of TIM4 blockade on activation of endogenous CD8+ T cells in the
blood of KP-OVA challenged mice. The percentage of IFN-γ+ CD8 and OVA specific-IFN-γ+ CD8 (Vα2/Vβ5+) as a function of total CD8 and Vα2/Vβ5+
T cells, respectively, at various time points after challenge. Isotype n= 5, αTIM4 n= 4, data represent one of two independent experiments. b–d Activation
of anti-tumor T cell responses in WT and Timd4−/− animals 7 days after challenge with KP-OVA. b Representative plots and frequencies of IFN-γ+
endogenous CD8+ T cells in MLN. c Absolute numbers of CD8+ T cells and d OVA-specific CD8+ T cells (pentamers+) accumulated at tumor site. Data
are representative of two experiments (n= 5 mice/group). e–g Lethally irradiated CD45.1 WT mice were injected with a 1:1 mixture of CD45.2 bone
marrows of the indicated genotypes to generate bone marrow chimeras. Ten weeks later mice were inoculated with KP-OVA tumors. e Representative
plots and frequencies of IFN-γ+ CD8+ T cells in MLN 10 days after tumor challenge (n= 6 mice/group). f Absolute numbers and quantification of CD8+
T cells accumulated at tumor site with Batf3−/−;WT n= 6 and Batf3−/−;Timd4−/− n= 5 mice. g Tumor growth in bone marrow chimeras was assessed
28 days after tumor challenge. Representative sections and quantification of tumor nodules calculated automatically on four consecutive sections of three
lobes/animal and expressed as a function of the total lobe area. Each value in the plot represents the average of the three lobes and four sections for
each mouse. All data are mean ± SEM. Significance was determined by two-way ANOVA followed by Sidak’s post-test for a, two-tailed unpaired t-test for
b–f, and two-tailed Mann–Whitney test for g. Source data are provided as a Source Data file.
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acquisition of tumor antigens by cDC1 resident in different
tumor tissue have been less investigated. TIM4 binding to PtdSer
in macrophages is key to engulf and clear dying cells and its
genetic deletion promotes development of autoimmunity40,46–48.
The pattern of expression and specific function of TIM4 in the
DCs compartment has remained controversial, likely because
of a lack of proper definition of DCs subset in past
analysis26,28,29,49–51. To fill this gap, we performed an extensive
characterization of DCs subsets across mouse tissues using
recently established gating strategies38. Besides the well-
established expression in most tissue resident macrophages, we
found a selective expression of TIM4 in mouse lung cDC1 that
was higher than in any other tissues DCs. Curiously, alveolar lung
macrophages are among the few resident macrophages that do
not express TIM4. It will be extremely intriguing to identify the
tissue factors that control transcriptional and epigenetic regula-
tion of TIM4 expression52,53 in steady state myeloid cells. A
second important issue relates to the function of TIM4 in tumors
and the mechanism behind receptor downregulation. TIM4
expression was reported to be upregulated in macrophages and
DCs infiltrating melanoma and mammary mouse tumors, and
to be associated with suppression of immune responses in col-
orectal mouse models29,31,54. In contrast, mouse lung tumors do
not induce recruitment of myeloid cells expressing TIM4 but
rather suppress its expression on cDC1, ablating T cell priming.
These observations suggest a highly specific tissue and context
dependent regulation, that would be important to investigate in
more tumor types and human tumors. A recent report showed
decrease of TIM4 and consequent loss of clearance in aging
macrophages caused by p38 activation55, suggesting a possible
mechanism of receptor loss in cDC1.
In this study, we used blocking antibodies and genetic deletion
to demonstrate the key role of TIM4 in engulfment of dying cells
and tumor cells and cross-presentation of cell associated antigens
by lung cDC1. Moreover, TIM4 blockade inhibited responses to a
combination of immunogenic drugs previously shown to induce
T cell responses in this same tumor model34,56, indicating its role
in promoting processing of released antigens. Together these
evidences underscore the role of TIM4 in cDC1 as a PtdSer
receptor implicated in capture of tumor antigens in cDC1, which
contributes to surveillance of nascent tumors and initiation of
tumor protective responses in mouse lung tumors. These findings
somehow conflict with a previous study showing that TIM4
induces degradation of tumor antigens by autophagy, thereby
inhibiting immunity29. This discrepancy likely arises from the
different antigen processing machinery in bone-fide cDC1 as
opposed to macrophages or CD11c/MHC-IIhigh cells and the
different tumor tissue analyzed.
Gene expression from the Cancer Genoma Atlas (TCGA)
showed a correlation between Timd4 transcripts and a gene sig-
nature for human cDC18, and effector CD8 T cells and better
survival for patients expressing high levels of cDC1 and Timd4. In
Fig. 6 TIM4 is required for tumor rejection induced by immunogenic chemotherapy. a Scheme of experimental design. Mice were challenged with KP cells
and left untreated or treated with oxa/cycl and anti-TIM4 or isotype as depicted in the scheme. b, c Analysis of the CD8/CD4 T cell ratio in the MLNs (b),
Untreated n= 10, Oxa/Cycl+Isotype n= 9, Oxa/Cycl+αTIM4 n= 9; and in the lungs (c), Untreated n= 10, Oxa/Cycl+Isotype n= 10, Oxa/Cycl+αTIM4
n= 9; of mice 2 weeks after the last treatment. Data are from two independent experiments. d Effect of TIM4 blockade on the efficacy of the immunogenic
chemotherapy. Tumor burden was assessed at day 28 by calculating the area covered by tumor nodules on four consecutive sections of three lobes/animal
and expressed as a function of the total lobe area. Results are from untreated n= 13, Isotype+Oxa/Cycl n= 14 and Oxa/Cycl+αTIM4 n= 14 in two
independent experiments. eWT and Batf3−/− mice were challenged with KP cells and treated with oxa/cycl or left untreated. Treatment efficacy is expressed
as the percentage of reduction in tumor area over not treated control calculated in 14 WT and 4 Batf3−/− mice. All data are expressed as mean ± SEM.
Significance was determined by one-way ANOVA followed by Tukey’s post-test for b–d and two-tailed Mann–Whitney test in e. Source data are provided as a
Source Data file.
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addition, a small trial showed a better response to checkpoint
blockade in patients, suggesting an association between TIM4
expression and protective immune responses in human lung
tumors. Further analysis of scRNA-seq data, flow cytometry and
immunohistochemistry are needed to establish the precise pattern
of expression across human tissues and its significance for the
human disease.
In conclusion, this study identifies TIM4 as a lung cDC1
phagocytic receptor implicated in immune surveillance of early
murine tumors, that is targeted at later stages of tumor pro-
gression impairing antitumor responses. Initial evidences support
the potential of TIM4 as a biomarker for stratification of human
lung tumors.
Methods
Mice. C57BL/6 mice were purchased from Envigo Laboratories and maintained in
sterile isolators at the ICGEB animal Bioexperimentation facility. Ethical and
experimental procedures were reviewed and approved by the ICGEB Animal Welfare
board, meeting the requirements of the EU Directive 2010/63/EU. Timd4−/− mice
(Miyanishi et al.40) were maintained under pathogen-free conditions at Osaka Uni-
versity and Experiments were approved by the Animal Care and Use Committee of
the Research Institute of Microbial Diseases, Osaka University and part of the colony
was transferred at ICGEB. The following strains were from Jackson Laboratories:
KrasG12D p53−/− (DuPage et al.33); B6.129S(C)-Batf3tm1Kmm/JBatf3−/−; OT-I and
OT-II (C57BL/6-Tg (TcraTcrb). These strains were maintained under pathogen-free
conditions at Brescia University, King’ College, and in sterile isolators at ICGEB,
respectively. OTI were crossed to congenic CD45.1 mice for tracking experiments.
Experiments on the KrasG12D p53−/− strain were approved by the Italian Ministry of
Health (approval number 165/2017-PR, issued on 20/02/2017). All experiments
performed at the ICGEB animal facility were approved by Italian Ministry of Health
(approval number 1155/206-PR and 646/2019-PR).
Cell lines. The transplantable KP tumor model has been isolated from primary
lung tumors of C57BL/6 KP mice (K-rasLSLG12D/+; p53fl/fl mice)57. The line called
(LG1233) was kindly provided by Dr. Tyler Jacks (Massachusetts Institute of
Technology, Cambridge, USA) in July 2015. Generation of the cell line is described
in the ref. 57. The cell line was not authenticated. To generate KP-OVA cells, KP
cells were transduced with the lentiviral vector Pdual-liOVAha-PuroR, encoding Ii-
OVA (kindly provided by David Murrugarren, CIB, Navarra). After puromycin
selection, cells were subcloned and single cell clones were tested for HA expression
by intracellular staining using anti-HA antibody (clone 3F10, Roche). To generate
KP-BFP cells the KP line has been transduced with a pAIP-BFP lentiviral vector.
This vector was obtained by adding XbaI and NotI sites to the BFP gene from
plasmid pU6-(BbsI) CBh-Cas9-T2A-BFP-P2A-Ad4E1B (Addgene plasmid 64218),
and inserting it into the lentiviral vector pAIP (Addgene plasmid 74171) under
the control of the SFFV promoter. The Lewis lung carcinoma cell line 3LL (LL2,
LLC/1) has been purchased by the ATCC (CRL-1642) in October 2014.
All cell lines were maintained in DMEM media supplemented with 10% fetal
bovine serum (FBS, Euroclone) and Gentamicin (50 μg/mL, Gibco) and routinely
tested for mycoplasma contamination. Cells were expanded to passage 3 and stored
in aliquots in liquid nitrogen. Cells used for in vivo challenge were been passed less
than five passages.
Establishment of orthotopic lung tumors. In order to establish lung orthotopic
tumors, 1 × 105 KP, 5 × 105 KP-OVA, or 5 × 105 KP-BFP cells were injected
intravenously in 100 µL PBS.
For KP and KP-BFP tumors early and late time points were defined as day
10–14 or 28–35. This definition of tumor stages is applied to all experiments with
the exception of some analysis, that were anticipated to day 5 or 7 as specified in
legends.
To establish 3LL tumors, 1 × 104 3LL cells were mixed at a 1:1 ratio with Geltre
LDEV-Free Reduced Growth Factor Basement Membrane Matrix (Gibco) in a final
volume of 20 µL, and injected into the left lung lobe by intercostal injection at the
median axillary line of C57BL/6 mice. For local delivery of KP cells, 1 × 104 KP
cells were injected as above and tissues were collected at day 28 after engraftment.
As ctrl, a group of mice was injected with PBS:Matrigel without tumor cells.
Fig. 7 Timd4 expression correlations and predictive value in human lung adenocarcinoma. a Correlation between Timd4 transcripts and gene signatures
for cDC1 and cytotoxic T cells (gene signatures described in Supplementary Table 2) within lung adenocarcinoma cases (LUAD) in TCGA. Pearson
correlation coefficient in the cor.test function of R stats package with two.sided as alternative hypothesis. b Kaplan–Meier survival curves showing probability
of survival for stage-I LUAD cases from the TCGA dataset (n= 219). The two groups with either high or low expression of cDC1 or cDC1+ Timd4, were
identified based on the classification rule described in the ref. 60 and detailed in methods. Survival curves were compared using the log-rank (Mantel–Cox)
test. c, d Patients from cohort GSE126044 that responded or not to PD-1 therapy were classified based on baseline pre-treatment expression of Timd4 (c),
cDC1 and CD8 cytotoxic T cells signatures (d). P values are calculated using the two-tailed Mann–Whitney test; responder n= 5, Non-responder n= 11.
Source data are provided as a Source Data file.
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Induction of autochthonous lung tumors. KP mice (K-rasG12D/+;p53fl/fl mice) at
8 weeks of age, were intranasally inoculated with 2.5 × 107 infectious particles of a
replication-deficient adenoviral vector with Cytomegalovirus promoter driving the
expression of the Cre recombinase protein in order to sporadically induce muta-
tions in lung cells, and promote lung tumor development as previously described
(DuPage et al.33). Mice were sacrificed 10 weeks after the adenovirus inoculation,
lungs were collected upon intracardiac perfusion with cold PBS and mechanically
and enzymatically treated as already described.
Lung tumor dissociation and dendritic cell isolation. Lung tissue, control or
infiltrated by tumors, were harvested after PBS lung circulatory perfusion. The
whole tissue was mechanically cut into small pieces and digested with Collagenase
type 2 (265 U/mL; Worthington) and DNase (250 U/mL; Thermo scientific) at
37 °C for 30’. Collagenase was then stopped by EDTA 10 mM and the cell sus-
pension was filtered using 70 μm cell strainer (Corning).
CD11c+ lung cells were separated by immunomagnetic sorting using CD11c
microbeads (Miltenyi Biotec) following manufacturer’s instructions. Dendritic cells
were purified by FACS sorting with FACS Aria II (BD Biosciences), using the gating
strategy shown in Supplementary Fig. 1c, after CD11c+ cells staining in PBS+ 2%
FBS with the following antibodies: CD11c-A647 (N418), CD103-PE (2E7) purchased
from Biolegend and SiglecF-BB515 (E50-2440), CD11b-BV421 (M1/70) and MHCII-
BV711 (M5/114.15.2) from BD Biosciences. For gene expression analysis up to 30,000
cells were sorted directly into 350 μL RLT buffer (Qiagen). For ex-vivo stimulation,
10,000 cDC1 were plated in U-bottom 96-well, stimulated with CpGB (1 µg/mL,
Invivogen) or DMXAA (25 µg/mL, Invivogen) for 3 h and then lysed in RLT buffer
for gene expression analysis.
Liver and skin dissociation. Livers were harvested after perfusion with 10 mL of
cold PBS, mechanically cut into small pieces and digested with collagenase IV
(0.2 mg/mL) and DNase I (0.03 mg/mL) 37 °C for 30 min. Collagenase was then
stopped by adding 3 mL of PBS+ EDTA 10 mM and the cell suspension was
filtered using 70 μm cell strainer (Corning). Red blood cells were lysed by using
RBC lysis buffer (Biolegend).
Mice ears were harvested and split into dorsal and ventral halves to expose the
inner dermal layer. Both halves were laid dermid side down in dispase solution
(Dispase 4 U/mL) 1 h at 37 °C. After incubation, the tissue was cut into small pieces
and digested 1 h at 37 °C with collagenase IV (0.2 mg/mL) and DNase (0.03 mg/
mL).
Cell suspensions were then processed for FACS staining.
Flow cytometry. The antibodies used for the experiments are listed in Supple-
mentary Table 4 and panels used to identify subsets are illustrated in Supple-
mentary Table 5. Viability was assessed by staining with LIVE/DEAD Fixable Aqua
Dead Cell Stain Kit (Life Technologies) or Annexin V/7AAD kit (Biolegend). For
cell staining, FcR binding sites were blocked by using αCD16/CD32 (93, Biole-
gend). Samples were then stained with specific antibodies in PBS+ 1% BSA and
fixed with PBS+ 1% PFA. To verify in vivo production of IL12p40, ctrl or KP-
bearing mice were treated with Brefeldin A (Sigma) iv for 6 h and then sacrificed.
Lungs were harvested, dissociated, and stained for the identification of lung-
resident cDCs. During all process cells have been maintained in the presence of
brefeldin A. For intracellular staining of OVA-HA, KP-OVA cells or lung cell
suspensions were fixed and permeabilized using Cytofix/Cytoperm solution (BD
Biosciences) following manufacturer’s instructions, and then stained with rat
monoclonal anti-HA (3F10, Roche) and then with anti-rat A647 (Thermo Fisher).
Absolute cell count was performed by adding TrueCount Beads (Biolegend) to
the samples following manufacturer’s instructions, or by multiplying the
percentage of the identified cell type by the total number of cells in each tissue. The
total number of cells were obtained by counting viable cell numbers with Trypan
blue (Gibco). After dead cell exclusion and exclusion of cell doublets, the following
populations were identified according to the gating strategy provided in
Supplementary Fig. 1c, d. For annexin labeling of tumor cells, annexin staining was
added to single cell suspension of lungs bearing day 7 KP-BFP tumors according to
manufacturer’s instructions and immediately analyzed.
Flow data were acquired with FACS Celesta (BD Biosciences) and analyzed with
Diva software (BD Bioscience) or FlowJo software (Tree Star, Inc.).
TIM4 blockade, CD8 depletion, and immunogenic chemotherapy. For TIM4
blocking studies healthy or tumor-bearing mice were treated with anti-TIM4
antibody (RMT-53, BioXCell) or isotype control (2A3, BioXCell) at the con-
centration of 250 µg/100 µL intravenously or intraperitoneally. The protocol for
TIM4 blockade (number of injections and timing) are described in each specific
experiment.
For CD8 depletion C57BL/6 mice were injected with anti-mouse CD8 (YTS
169.4, BioXCell) or isotype control (2A3, BioXCell) at the concentration of 200 µg/
100 µL intraperitoneally at day −1, +4, 8, 11 after KP-OVA implantation. Mice
were sacrificed 15 days after tumor inoculation to assess tumor burden and validate
CD8+ T cell depletion by FACS.
KP tumor-bearing mice were either left untreated or received chemotherapy
intraperitoneally (i.p.) at day 7 and 14 after tumor engraftment (Oxaliplatino,
2.5 mg/kg; Cyclophosphamide, 50 mg/kg, Tocris Bioscience). In these experiments,
mice were treated with anti-TIM4 antibodies or isotype control the day before
chemotherapy administration.
Detection of specific OVA-MHC-I complexes on cDC1. To detect specific MHC
class-I OVA complexes CD11c+ cells were isolated from KP-OVA early or late
tumors by microbeads and incubated for 1 h at 37 °C with PE-coupled 25-D1.16 mAb
(BioLegend). Cells were washed and stained with extracellular antibodies to identify
cDC1, cDC2, and AM and analyzed by flow cytometry. As negative control, CD11c+
cells were isolated from control lungs. For TIM4 blocking studies, mice were treated at
day −1 and 3 post KP-OVA inoculation with TIM4 blocking antibodies or isotype
control and lungs were harvested at day 7 for labeling as above.
Uptake of KP-BFP cells. Mice were challenged with KP-BFP tumor cells and lung
tissues were collected at different time points as indicated in the legends. Total lung
cell suspensions were stained to identify phagocytes, and the fraction of each subset
associated to BFP fluorescence was used to calculate the uptake index. To compare
uptake at early and late time points data were normalized against the numbers of
BFP cells in the lung tissue. In TIM4 blocking experiments, mice were treated with
anti-TIM4 antibodies or isotype control at day −1 and 3 w KP-BFP challenge and
lungs were harvested at day 5 post-tumor inoculation. Total lung cell suspensions
were labeled to identify BFP+ phagocytes. The frequency of phagocytes associated
to BFP fluorescence was assessed by flow cytometry and normalized on the fre-
quency of total CD45− BFP+ cells.
In vivo uptake, ex-vivo binding and engulfment of dying thymocytes. Thy-
mocytes were isolated from Balb/C animals and incubated for 5 h at 37 °C in RPMI
+ 10% FBS medium with Dexamethason (5 µM, Tocris). After incubation the
percentage of apoptotic cells assessed by AnnexinV-BV421/7AAD staining was
higher than 60%. For in vivo uptake, apoptotic cells were stained with 5 µM of
CellTrace™ Violet Cell Proliferation Kit (CTV, Thermo Fisher Scientific). After
staining, cells were resuspended in PBS at the concentration of 20 × 106 in 20 µL,
and injected intratracheally in control mice or mice bearing early or late KP
tumors. In TIM4 blocking experiments, C57BL/6 mice were treated the day before
apoptotic cell administration with anti-TIM4 antibody or isotype control (ip).
Lungs were harvested 2 h after apoptotic cell administration, dissociated and
stained for the identification of CTV+ lung resident phagocytes.
For in vitro analysis of internalization, apoptotic thymocytes were labeled with
5 µM of CFSE (BioLegend), washed extensively and co-cultured for 2 h with cells
sorted cDC1 derived from nLung, early or late KP tumor bearing lungs at
3DC:1thymocytes ratio. Cells were plated on fibronectin coated coverslips for 1 h.
For in vitro binding, isolated cDC1 derived from nLung or KP tumor bearing lungs
were first adhered to fibronectin-coated coverslips and co-cultured for 30 min with
thymocytes at 1DC:10thymocytes ratio. Uptake and binding were analyzed by
confocal microscopy using a 60× planar objective on a Zeiss 880 instrument. To
calculate the phagocytic index the fraction of cells containing at least one fragment
of green material within the intracellular space was scored, and divided by the total
number of DC on the coverslip. DCs were distinguished as they label positive for
CD11c used for cell sorting. To calculate binding, the fraction of DC showing at
least one contact with a green T cells was counted and divided by the total number
of DC on the coverslip.
Uptake of dying cells by Timd4−/− lung phagocytes. After perfusion with
HBSS/2 mM EDTA, lungs were processed using a GentleMACS dissociator (Mil-
tenyi Biotech) according to the manufacturer’s instruction, and treated at 37 °C for
30 min with 2 mg/mL Collagenase D (Roche Diagnostics) and 100 µg/mL DNase I
(Worthington) in DMEM containing 10% FBS. After passing through a 70-µm cell
strainer (BD Biosciences), cells were collected by centrifugation at 300×g for 5 min,
and suspended in PBS containing 2% FBS and 2mM EDTA. Dead and unwanted
cells were removed using EasySep™ Biotin Selection Cocktail (STEMCELL), and
biotinylated mouse MFG-E8 D89E, and the following biotinylated antibodies:
CD31 (390) and TER-119 (TER-119) from BioLegend, and CD3e (145-2C11),
CD19 (1D3) and Ly-6G/Ly-6C (RB6-8C5) from BD Biosciences. The remaining
cells were plated on 24-well plates at 2 × 105 cells per well. The 2 ×10 6 pHrodo-
labeled apoptotic thymocytes that had been prepared as described (Yanagihashi
et al.39) were added to the well, and incubated at 37 °C for 2 h. After washing with
PBS, the cells were stained with the antibodies described below, suspended in
20 mM CHES-NaOH buffer (pH 9.0) containing 150 mM NaCl and 2% FBS, and
analyzed by flow cytometry. The antibodies used are anti-CD45-APC/Fire750
(30-F11, BioLegend), anti-SiglecF-PerCP/eFluor710 (1RNM44N, Thermo Fisher
Scientific), anti-CD11c-APC (N418, BioLegend), anti-MHC II (I-A/I-E)-Alexa-
Fluor488 (M5/114.15.2, BioLegend), anti-CD103-PE/Cy7 (2E7, BioLegend), and
anti-XCR1-BV510 (ZET, BioLegend).
Ex vivo priming of OT-I cell by cell sorted cDC1. For ex-vivo T cell activation
assay, cDC1 isolated from early or late KP-OVA tumors were plated in U-bottom
96 wells and co-incubated with CFSE-labeled OTI T cells at the ratio 1:5 (104 cDCs
and 5 × 104 CD8+OTI). After 48 h of co-culture OTI T cell proliferation was
assessed by flow cytometry. For TIM4 blocking experiments, mice were treated the
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day before and 3 days after KP-OVA inoculation with anti-TIM4 antibodies or
isotype ctrl. In these experiments, mice were sacrificed 7 days post-tumor
engraftment and isolated lung-resident cDC1 or total mediastinal lymph node cells
were incubated with CD8+OTI cells. For T cell priming assay using cDC1 pulsed
ex-vivo DC1 isolated from nLung or late KP tumor-bearing lungs were plated 1 ×
104 in U-bottom 96-well, stimulated with polyI:C (1 μg/mL) and pulsed with class I
OVA peptide or OVA protein at the indicated doses. After 3 h stimulation, cells
were washed twice in PBS and co-incubated with 1 × 105 OT-I T cells. IL-2
production was detected in the supernatant after 16 h of co-incubation by ELISA
Max Standard sets (Biolegend), following manufacturer’s instructions.
Adoptive transfer and activation of OTI. 1 × 106 KP-OVA cells were injected iv
in wt or Batf3−/− mice to establish tumors. At day 14 post challenge 1 × 105
CD45.1+OTI CD8+ OVA-specific T cells were labeled with CFSE (5 µM, Biole-
gend) or CTV (5 µM, Thermo Fisher Scientific), and intravenously injected into
mice bearing early or late tumors. After 2 days from the injection mice were
sacrificed and lungs and MLN were collected, processed as described previously
and proliferation was verified by flow cytometry. In Batf3−/− experiments total
lung cells were re-stimulated ex-vivo with OVA class-I peptide SIINFEKL (2 µM),
and stained intracellularly with anti-IFN-γ antibody using the intracellular staining
kit BD Golgi STOP. In TIM4 blocking experiments, mice inoculated with KP-OVA
cells were treated at day −1 and +3 post-tumor inoculation with anti TIM4 or
isotype control, injected with CTV-labeled OTI cells at day 4 and sacrificed at day 7
to analyze OTI accumulation and proliferation in MLN.
Cross-presentation of OVA loaded tymocytes. CD8+ T cells were isolated
from lymph nodes of OTI mice by beads separation (CD8a+ T cell isolation kit,
Miltenyi Biotec) and labeled with CFSE (5 µM, Biolegend) following manu-
facturer’s instructions. 1 × 106 CFSE-labeled CD8+ OTI cells were injected i.v.
in healthy or early and late KP-bearing mice. The day after OTI injection, Balb/C
thymocytes were isolated and incubated for 1 h at 37 °C (RPMI+ 10%FBS+ β-
mercapthoethanol) with OVA protein (1 mg/mL) at the concentration of 107/mL.
After 1 h, Dexamethason (5µM) was added to the cell suspension and cells were
incubated 4–5 h at 37 °C. Apoptosis was evaluated by AnnexinV/7AAD staining.
Apoptotic cells (apoptosis > 90%) were injected intra-trachea (20 × 106 in 20 µL)
with PolyI:C (1 µg/mouse). In TIM4 blocking experiments, mice were iv injected
with anti-TIM4 antibody or isotype control 5 h before apoptotic cells adminis-
tration (250 µg/mouse). Cross-presentation of cell associated antigens was assessed
48 h after intratracheal injection, by verifying OTI accumulation and proliferation
in mediastinal lymph node by flow cytometry.
Activation of endogenous anti-tumor CD8+ T responses. For the detection of
endogenous anti-tumor CD8+ T cells in KP-OVA bearing mice, blood was col-
lected at day 7, 14, 21, and 28 post-tumor inoculation. After red blood cell lyses,
cells were stimulated with SIINFEKL (2 µM) 37 °C for 4 h in the presence of Golgi
Stop (BD Biosciences) to allow accumulation of intracellular cytokines. After via-
bility and surface marker staining, cells were fixed and permeabilized using
Cytofix/Cytoperm solution (BD Biosciences) following manufacturer’s instructions,
and then stained with αIFNγ-PE (XMG1.2, Biolegend). For the analysis of the
activation state of endogenous tumor-infiltrating CD8+ T cells, KP-OVA tumor
bearing lungs were harvested at early and late time points, dissociated and cell
suspensions were processed as described above for evaluation of IFNγ production.
Timd4−/− mice were injected with 2 × 105 KP-OVA cells and sacrificed 7 days
post-tumor inoculation. We analyzed IFNγ production in lung-draining lymph
nodes and the accumulation of endogenous anti-tumor CD8+ T cells in the lungs
by using R-PE labeled Pro5® MHC H-2KbPentamers (Proimmune) following
manufacturer’s instructions. Briefly, total lung cell suspension was stained with R-
PE labeled Pro5®MHC H-2KbPentamers for 45 min at 4 °C, washed and stained to
identify CD8 using the gating strategy shown in Supplementary Fig. 1d.
Endogenous T cell response was also analyzed as described above in BM
chimeric mice. BM chimeras were injected with KP-OVA cells and sacrificed at
10 days post-tumor inoculation. Lung draining LNs were ex vivo stimulated and
stained for IFNγ production, and lungs were processed and stained for assessing
the endogenous CD8+ T cell accumulation at tumor site.
Bone-marrow mixed chimeras. To generate bone marrow mixed chimeras,
CD45.1 mice were lethally irradiated with 450 rad followed by a second dose of
450 rad 4 h apart. The day after irradiation mice were reconstituted with 5 × 106
total BM cells of a 1:1 mixture (Timd4−/−: Batf3−/− or wt: Batf3−/−) by intra-
venous injection. Before we initiated the experiments, mice were allowed to engraft
for 10 weeks and engraftment was assessed by analyzing the percentage of CD45.2
(donor cells) over the CD45.1 (recipient cells) in the blood. Animals were then
injected iv with KP-OVA cells (1 × 106) and sacrificed at early (10 days) or late
(28 days) time points for analysis. To check the chimerism, lung-resident cDC1
and peritoneal macrophages were stained for TIM4 expression.
Real time PCR. Total RNA was extracted from isolated cDC1 by using the RNeasy
MicroKit (Qiagen) according to manufacturer’s instruction. cDNA was synthesized
using SuperScript VILO (Invitrogen) and real-time PCR for gene expression was
performed using SsoFast EvaGreen Supermix (Biorad) with specific primers for
IL12a, IL12b, Ifna, and Ifnb are listed in Supplementary Table 3.
Immunohistochemistry on mouse samples. To evaluate tumor burden lung
tissues were harvested, fixed in formaldehyde 10% and paraffin embedded fol-
lowing standard procedure. Consecutive sections every 200 µm were dewaxed and
rehydrated and stained with the H&E (Bio-Optica, Milano Spa). The area of tumor
nodules was quantified over consecutive sections and averaged (three sections/
sample). Measurements and automatic thresholding were performed using Image J.
The area occupied by tumor nodules was expressed as a function of the total lung
lobe area. For CD8+ T cells infiltration and HA expression, sections were treated
with antigen-retrieval solution (Vector laboratories) for 20 min at 120 °C. Slides
were treated for 2 min in H2O2 to block endogenous alkaline phosphatase. After
blocking in 10% goat serum in 0.1% Tween20 for 30 min slides were incubated
overnight in a humidified chamber in a 1:500 dilution of anti-mouse CD8 (Invi-
trogen cat 14–0808–82) in blocking buffer or anti-HA 1:50 (Roche). Detection was
performed using the ImmPRESS polymer detection system (Vector Laboratories),
according to manufacturer’s Instructions. Ilastik software was used to automatic
detect and segmentate CD8+ cells. Segmented images were further automatic
analyzed for the number of foci using Image J software. The number of tumor-
infiltrating CD8+ T cells was normalized on tumor nodule area.
Gene expression profiling of ex vivo purified cDC1 cells. Gene expression
profiling was performed on Mouse Gene 2.0 ST arrays (Affymetrix, Santa Clara,
CA, USA). Total RNA was extracted using TriPure (Roche) from ex vivo purified
cDC1 cells from the lungs of healthy and KP tumor-bearing mice (n= 4 and n= 3
independent samples, respectively). RNA quality and purity were assessed on the
Agilent Bioanalyzer 2100 (Agilent Technologies, Waldbronn, Germany); RNA
concentration was determined using the NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies Inc.). RNA was then treated with DNaseI (Ambion). In
vitro transcription, hybridization and biotin labeling were performed according to
Affymetrix 3’IVT protocol (Affymetrix).
All microarray data analyses were performed in R (version 3.4.2) using
Bioconductor libraries (BioC 3.5) and R statistical packages. Probe level signals
were converted to expression values using robust multiarray average procedure
RMA of Bioconductor affy package, and a custom definition file for mouse Gene
2.0 ST arrays based on Entrez genes from BrainArray (version 22.0.0; http://
brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/22.0.0/entrezg.
asp). Raw data are available at Gene Expression Omnibus under accession number
GSE119574.
To identify differentially expressed genes, we compared the expression levels of
ex vivo purified cDC1 cells from the lungs of healthy and KP-tumor bearing mice
using the Significance Analysis of Microarray (SAM; algorithm coded in the samr R
package58. In SAM, we estimated the percentage of false positive predictions (i.e.,
false discovery rate, FDR) with 100 permutations and selected those probe sets with
FDR ≤ 5% and absolute fold change larger than a selected threshold (e.g., ≥2) in the
comparison of cDC1 cells from tumor-bearing and healthy mice (Supplementary
Table 1).
Global unsupervised and supervised clusterings were performed using the
function hclust of R stats package with Pearson correlation as distance metric and
average agglomeration method. Gene expression heatmaps have been generated
using the function heatmap.2 of R gplots package after row-wise standardization of
the expression values. The volcano plot, showing the most significantly
differentially expressed genes in the comparison of ex- vivo purified cDC1 cells
from tumor and healthy mice, was generated using the ggplot function of the
ggplot2 R package. P-values were derived from SAM q-values using the function
samr.pvalues.from.perms of the samr R package (Supplementray Table 1).
Functional over-representation was performed using Gene Set Enrichment
Analysis (GSEA; http://software.broadinstitute.org/gsea/index.jsp) and the curated
gene sets of the Molecular Signatures Database (MSigDB) derived from the
Hallmark pathway collection (http://software.broadinstitute.org/gsea/msigdb/
collections.jsp). Prior to GSEA analysis, we converted mouse Entrez IDs into the
corresponding human homologous genes using the HUGO Gene Nomenclature
Committee (HGNC) database (https://www.genenames.org/cgi-bin/hcop). Gene
sets were considered significantly enriched at FDR ≤ 0.25 when using Signal2Noise
as metric and 1000 permutations of gene sets. The dot plot, showing the most
significantly enriched and depleted gene sets in cDC1 sorted from lungs with
established KP tumors, was generated using the ggplot function of the ggplot2 R
package. Immgen data were downloaded from the Consortium webpage and linear
expression values for Timd4 were replotted in Graphpad.
Collections of lung adenocarcinoma. Gene expression data (RSEM gene nor-
malized) and clinical information of the TCGA lung adenocarcinoma (LUAD)
were downloaded from the Broad GDAC Firehose Portal and used as is. Tran-
scriptional profiles of non-small-cell lung cancer patients responding and non-
responding to anti-PD-1 treatment were downloaded from Gene Expression
Omnibus GSE12604459. Raw counts have been converted to CPM and log-CPM
values using the cpm function of the edgeR package in R.
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Average signature expression has been calculated as the standardized average
expression of all signature genes in sample subgroups (e.g., histological grade,
response to therapy). The gene sets used for the signatures and the relevant
literature are illustrated in Supplementary Table 2. To identify two groups of
tumors with either high or low expression of a gene set, we used the classification
rule described in the ref. 60. Briefly, we classified tumors as “low” if the gene set
score was lower than the 25th percentile of the distribution of the gene set score
and as “high” otherwise. This classification was applied to the expression values of
the TCGA LUAD dataset, early stages. To evaluate the prognostic value of a gene
set, we estimated the overall survival probability using the Kaplan–Meier method
and compared the Kaplan–Meier curves using the log-rank (Mantel–Cox) test. P
values were calculated according to the standard normal asymptotic distribution.
Survival analysis was performed in GraphPad Prism.
Single-cell RNA-seq data analysis. Murine lung scRNA-seq data have been obtained
from Tabula Muris61. Briefly, we downloaded from the Tabula Muris website
(https://tabula-muris.ds.czbiohub.org/) the R object file containing cell annotations
and clustering information of cells analyzed using FACS-based cell capture in plates.
tSNE plots of all cell types and of the “dendritic cell/macrophage” subset have been
generated using Seurat R package62. 3D scatterplots were generated with the plot3d
function of the rgl R package. Control and KP tumor murine lungs scRNA-seq data
were obtained from the ref. 16. Briefly, we downloaded from the GitHub repository
associated to the publication (https://github.com/effiken/Maier_et_al_nature_2020)
the R object file containing expression values and cell annotations. Differential
expression analysis was performed using Seurat R package.
Statistic. Primary data were collected in Microsoft Excel and statistical analysis
were performed using Graphpad Prism 6. For comparison between two or more
groups with normally distributed datasets two-tailed Student’s T-test, one-way
ANOVA or two-way ANOVA were used as appropriate. The non-parametric
Kruskal–Wallis test with Dunn’s multiple comparison was performed to compare
three or more unmatched groups. P values ≤ 0.05 were considered significant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All microarray raw data generated for the present study, along with gene expression
matrices and metadata for each sample, are publicly available in Gene Expression
Omnibus (GEO) under accession code [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE119574]. RSEM gene normalized data and clinical information of the TCGA
lung adenocarcinoma (LUAD) were downloaded from the Broad GDAC Firehose Portal
[http://firebrowse.org/?cohort=LUAD&download_dialog=true]. RNA-seq raw counts of
non-small-cell lung cancer patients responding and non-responding to anti-PD-1
treatment were downloaded from GEO [https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE126044]. The scRNA-seq data of murine lung were obtained from Tabula
Muris [https://tabula-muris.ds.czbiohub.org/] as R object file containing cell annotations
and clustering information of cells analyzed using FACS-based cell capture in plates. The
scRNA-seq data of control and KP tumor murine lungs were downloaded from https://
github.com/effiken/Maier_et_al_nature_2020 as an R object file containing expression
values and cell annotations [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE131957]. The gene sets of the Hallmark pathway collection were downloaded
from the Molecular Signatures Database (MSigDB) of the Broad Institute [http://
software.broadinstitute.org/gsea/msigdb/collections.jsp; version 6.2]. Source data are
provided with this paper. All other data supporting the findings of this study are available
within the Article, Supplementary Information or from the corresponding authors on
reasonable request.
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